Devonian annonce l’initiation de l’étude clinique de Phase IIa du Thykamine(MC) chez les patients atteints de Dermatite Atopique légère à modérée
November 09, 2017 08:45 ET
|
Groupe Santé Devonian Inc.
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 09 nov. 2017 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX...
Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine™ in Adult patients with Mild-to-Moderate Atopic Dermatitis
November 09, 2017 08:45 ET
|
Devonian Health Group Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ("Devonian" or the "Corporation")...
WOWIO, INC. Acquires Land to be developed into low cost housing in Northern California
November 09, 2017 06:30 ET
|
Wowio, Inc.
WOWIO Continues to Build its base of new Businesses Henderson, NV, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Wowio, Inc. (OTC Pink: WWIO) “WWIO or The Company” has entered into an agreement for its wholly...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
October 09, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Earth Science Tech Inc. Signs Contract with CDBQ to Advance Phase-2 Rollout on it’s CBD Patents
August 01, 2017 08:25 ET
|
Earth Science Tech, Inc.
Hollywood, FL, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotechnology company that operates in the fields of hemp...
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
July 26, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
May 17, 2017 16:05 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
April 24, 2017 07:15 ET
|
Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...
Akari Therapeutics to Present at the Jefferies Complement Symposium
April 03, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...